Cytokinetics Inc (NASDAQ: CYTK) kicked off on Monday, down -4.97% from the previous trading day, before settling in for the closing price of $71.56. Over the past 52 weeks, CYTK has traded in a range of $25.98-$110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 12.30% over the last five years. While this was happening, its average annual earnings per share was recorded 18.27%. With a float of $100.94 million, this company’s outstanding shares have now reached $101.64 million.
The firm has a total of 423 workers. Let’s measure their productivity.
Cytokinetics Inc (CYTK) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 3.48%, while institutional ownership is 108.23%. The most recent insider transaction that took place on Apr 09 ’24, was worth 2,422,918. In this transaction EVP Research & Development of this company sold 32,605 shares at a rate of $74.31, taking the stock ownership to the 138,567 shares. Before that another transaction happened on Mar 05 ’24, when Company’s EVP Research & Development sold 32,604 for $67.56, making the entire transaction worth $2,202,606. This insider now owns 138,973 shares in total.
Cytokinetics Inc (CYTK) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Take a look at Cytokinetics Inc’s (CYTK) current performance indicators. Last quarter, stock had a quick ratio of 6.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 944.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.14 in the next quarter and is forecasted to reach -3.19 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Analysing the last 5-days average volume posted by the [Cytokinetics Inc, CYTK], we can find that recorded value of 1.02 million was lower than the volume posted last year of 3.12 million. As of the previous 9 days, the stock’s Stochastic %D was 38.35%. Additionally, its Average True Range was 3.34.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 46.90%, which indicates a significant increase from 6.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.67% in the past 14 days, which was lower than the 117.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $72.23, while its 200-day Moving Average is $49.78. Now, the first resistance to watch is $70.58. This is followed by the second major resistance level at $73.17. The third major resistance level sits at $74.73. If the price goes on to break the first support level at $66.43, it is likely to go to the next support level at $64.87. Should the price break the second support level, the third support level stands at $62.28.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
The company with the Market Capitalisation of 7.11 billion has total of 104,576K Shares Outstanding. Its annual sales at the moment are 7,530 K in contrast with the sum of -526,240 K annual income. Company’s last quarter sales were recorded 1,670 K and last quarter income was -136,900 K.
